Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
Sponsor: RenJi Hospital
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Official title: NEOadjuvant Iparomlimab and Tuvonralimab (QL1706) Plus Chemotherapy in Patients With Hormone Receptor Positive And HER2-Negative Breast Cancer: a Prospective, Single Arm, Multicenter Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
55
Start Date
2026-03
Completion Date
2031-12
Last Updated
2026-02-09
Healthy Volunteers
No
Interventions
Iparomlimab and Tuvonralimab (QL1706)
5.0mg/kg qw, start from C1D15
Paclitaxel
80mg/m\^2 qw
Carboplatin
AUC=1.5, D1, 8, 15, every 28 days
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China